russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLCrussjcardiol-2370Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWСОСТОЯНИЕ И ФУНКЦИОНИРОВАНИЕ БЕТА-АДРЕНОРЕЦЕПТОРОВ И ИХ МОДИФИКАЦИЯ НА ФОНЕ ЛЕЧЕНИЯ БЕТА-БЛОКАТОРАМИ БОЛЬНЫХ С АРТЕРИАЛЬНОЙ ГИПЕРТОНИЕЙ И С ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮStatus and function of betaDadrenoreceptors and their modification during betaDblocker treatment in patients with arterial hypertension and chronic heart failureМанешинаО. А.ManeshinaO. A.

кафедра клинической фармакологии

ЛеоноваМ. В.LeonovaM. V.

кафедра клинической фармакологии

БелоусовЮ. Б.BelousovYu. B.

кафедра клинической фармакологии

Российский государственный медицинский университетRussian Federation200528102005058086Copyright © Манешина О.А., Леонова М.В., Белоусов Ю.Б., 20052005Манешина О.А., Леонова М.В., Белоусов Ю.Б.Maneshina O.A., Leonova M.V., Belousov Y.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/2370

Despite modern pharmacology's advances in developing new medication forms, some patients still are therapy-resistant. This review is devoted to beta-adrenoreceptor status, function, and modification during beta-adrenoblocker treatment in patients with arterial hypertension and chronic heart failure. Possible causes of beta-blocker resistance are described, including receptor-medication interaction, and beta-adrenoreceptor polymorphism.

β-адреноблокаторыполиморфизм β-адренорецепторовхроническая сердечная недостаточностьbeta-adrenoblockersbeta-adrenoreceptor polymorphismchronic heart failureReferencesОльбинская Л.И., Сизова Ж.М. Фармакотерапия хронической сердечной недостаточности/Москва, «Русский врач», 2002: 6-7.Ольбинская Л.И., Сизова Ж.М. Фармакотерапия хронической сердечной недостаточности/Москва, «Русский врач», 2002: 6-7.Аронов Д.М. Статины снижают смертность и улучшают течение атеросклеротических заболеваний//Consilium Medicum 2001, 36: (10), 456-463.Аронов Д.М. Статины снижают смертность и улучшают течение атеросклеротических заболеваний//Consilium Medicum 2001, 36: (10), 456-463.Consensus recommendations for the management of chronic heart failure//Am. J. Cardiol. 1999;83(suppl. 2A):Al-38.Consensus recommendations for the management of chronic heart failure//Am. J. Cardiol. 1999;83(suppl. 2A):Al-38.The 6th of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure/NIH Publication 1997;98:1080.The 6th of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure/NIH Publication 1997;98:1080.Обрезан AT., Вологдина И. В. Хроническая сердечная недостаточность//«Вита-Нова», Санкт-Петербург. 2002:178.Обрезан AT., Вологдина И. В. Хроническая сердечная недостаточность//«Вита-Нова», Санкт-Петербург. 2002:178.Humma L.M., Terra S.G. Pharmacogenetics and Cardiovascular Disease. Am. J. Health-Syst. Pharm. 59(13):1241-1252.Humma L.M., Terra S.G. Pharmacogenetics and Cardiovascular Disease. Am. J. Health-Syst. Pharm. 59(13):1241-1252.WUielmsen L., Rosengren A., Eriksson H. et al. Heart Failure in the general population of men -morbidity, risk factors and prognosis//J. Int. med. 2001;249:253-61.WUielmsen L., Rosengren A., Eriksson H. et al. Heart Failure in the general population of men -morbidity, risk factors and prognosis//J. Int. med. 2001;249:253-61.Kannel W.B. Vital epidemiologic clues in heart failure//J. Clin. Epidemiol. 2000;229-35.Kannel W.B. Vital epidemiologic clues in heart failure//J. Clin. Epidemiol. 2000;229-35.Adams K.F. New epidemiologic perspectives concerning mild-to-moderate heart failure//Am. J. Med. 2001:110:6S-13S.Adams K.F. New epidemiologic perspectives concerning mild-to-moderate heart failure//Am. J. Med. 2001:110:6S-13S.Сергеев П.В., Галенко-Ярошевский П.А., Шимановский Н.Л. «Очерки биохимической фармакологии» РЦ «Фармединфо», Москва. 1996.Сергеев П.В., Галенко-Ярошевский П.А., Шимановский Н.Л. «Очерки биохимической фармакологии» РЦ «Фармединфо», Москва. 1996.Сергеев П.В., Шимановский Н.Л., Петров В.И. «Рецепторы» Москва -Волгоград, 1999.Сергеев П.В., Шимановский Н.Л., Петров В.И. «Рецепторы» Москва -Волгоград, 1999.Kenakin T. Drags and Receptors Drags, 1990 40 (5): 666-687.Kenakin T. Drags and Receptors Drags, 1990 40 (5): 666-687.Егорова H.A., Манешина О.А. Применение метопролола при стенокардии//Фарматека №8. 2004.Егорова H.A., Манешина О.А. Применение метопролола при стенокардии//Фарматека №8. 2004.Белоусов Ю.Б., Моисеев B.C., Лепахин В.К.//Клиническая фармакология и фармакотерапия. Москва, «Универсум Паблигпинг» 2000.Белоусов Ю.Б., Моисеев B.C., Лепахин В.К.//Клиническая фармакология и фармакотерапия. Москва, «Универсум Паблигпинг» 2000.Yamada S., Ohkura T., Uchida S. et al. A sustained increase in beta-adrenoreceptors during long-term therapy with metoprolol and bisoprolol in patients with heart failure from idiopathic dilated cardiomyopathy//Life Sci. 1996; 58: 1737-44.Yamada S., Ohkura T., Uchida S. et al. A sustained increase in beta-adrenoreceptors during long-term therapy with metoprolol and bisoprolol in patients with heart failure from idiopathic dilated cardiomyopathy//Life Sci. 1996; 58: 1737-44.Ishida S., Makino N., Masutomo К. et al. Effect of metoprolol on the beta-adrenoceptor density of lymphocytes in patients with dilated cardiomyopathy//Am. HeartJ. 1993; 125(5 Pt 1): 1311-5.Ishida S., Makino N., Masutomo К. et al. Effect of metoprolol on the beta-adrenoceptor density of lymphocytes in patients with dilated cardiomyopathy//Am. HeartJ. 1993; 125(5 Pt 1): 1311-5.Yingxin P., Jiang S., Xiaoyong Q. et al. Changes and significance of subtype function of beta-adrenoreceptors in left ventricular remodeling of hypertension//Jpn. HeartJ. 2003 Nov; 44(6): 933-42.Yingxin P., Jiang S., Xiaoyong Q. et al. Changes and significance of subtype function of beta-adrenoreceptors in left ventricular remodeling of hypertension//Jpn. HeartJ. 2003 Nov; 44(6): 933-42.Prakash A., Markham A. Metoprolol: A Review of its Use in Chronic Heart failure//Drags 2000 Sep; 60(3): 647-678.Prakash A., Markham A. Metoprolol: A Review of its Use in Chronic Heart failure//Drags 2000 Sep; 60(3): 647-678.Белоусов Ю.Б. Место метопролола в лечении хронической сердечной недостаточности//Фарматека № 4-2002, 33-43.Белоусов Ю.Б. Место метопролола в лечении хронической сердечной недостаточности//Фарматека № 4-2002, 33-43.Peng Y., Ma S., Zhang S. et al. Clinical significance of changes in beta-adrenoreceptors in peripheral lymphocytes in patients with essential hypertension//Chin. med. 2000 Dec; 113 (12): 1064 -7.Peng Y., Ma S., Zhang S. et al. Clinical significance of changes in beta-adrenoreceptors in peripheral lymphocytes in patients with essential hypertension//Chin. med. 2000 Dec; 113 (12): 1064 -7.Parfenova E.I., Krasnikova T.L., D'iakonova E.G. et al. Density of lymphocyte beta-2 adrenoreceptors in the course of hypertension//Klin. Med. (Mosk). 1995;73(5):38-40 [Abstracts].Parfenova E.I., Krasnikova T.L., D'iakonova E.G. et al. Density of lymphocyte beta-2 adrenoreceptors in the course of hypertension//Klin. Med. (Mosk). 1995;73(5):38-40 [Abstracts].Halawa B. Arterial hypertension. Density of alpha 1 and alpha 2 adrenergic receptors in blood platelets, beta adrenergic receptors in the lymphocytes and serum catecholamine levels//Kardiol. Pol. 1991;35(12):340-4. 25.Halawa B. Arterial hypertension. Density of alpha 1 and alpha 2 adrenergic receptors in blood platelets, beta adrenergic receptors in the lymphocytes and serum catecholamine levels//Kardiol. Pol. 1991;35(12):340-4. 25.Irodova N.L., Krasnikova T.L., Masenko V.P. et al. Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrenergic receptors//Ter. Arkh. 2002;74(8): 30-4 [Abstracts].Irodova N.L., Krasnikova T.L., Masenko V.P. et al. Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrenergic receptors//Ter. Arkh. 2002;74(8): 30-4 [Abstracts].Teerlink J.R., Massie B.M. Beta-adrenergic blocker mortality trials in congestive heart failure//Am. J. Cardiol. 1999;84: R94-102.Teerlink J.R., Massie B.M. Beta-adrenergic blocker mortality trials in congestive heart failure//Am. J. Cardiol. 1999;84: R94-102.Моисеев В.С. Сердечная недостаточность и достижения генетики//Сердечная недостаточность. 2000 Т. 1-№4, 121-130Моисеев В.С. Сердечная недостаточность и достижения генетики//Сердечная недостаточность. 2000 Т. 1-№4, 121-130Poole-Wilson P., Remme W.J. COMET: a multicentre randomized double-blind study to compare the effect of carvedilol and metoprolol on mortality and morbidity in patients with moderate or severe congestive heart failure (NYHA II-IV) [Abstract]//Cardiovasc. Drugs Ther. 1999; 13: 24.Poole-Wilson P., Remme W.J. COMET: a multicentre randomized double-blind study to compare the effect of carvedilol and metoprolol on mortality and morbidity in patients with moderate or severe congestive heart failure (NYHA II-IV) [Abstract]//Cardiovasc. Drugs Ther. 1999; 13: 24.MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure; Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)//Lancet 1999; 353: 2001-7.MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure; Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)//Lancet 1999; 353: 2001-7.The RESOLVD Inverstigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study//Circulation 2000; 101: 378-8.The RESOLVD Inverstigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study//Circulation 2000; 101: 378-8.Sigmund M., Jacob H., Becker H., et al. Effect of metoprolol on myocardial beta-adrenoreceptors and Gia-proteins in patients with congestive heart failure//Eur. J. Clin. Pharmacol 1996; 51: 127-32.Sigmund M., Jacob H., Becker H., et al. Effect of metoprolol on myocardial beta-adrenoreceptors and Gia-proteins in patients with congestive heart failure//Eur. J. Clin. Pharmacol 1996; 51: 127-32.Lowes B.D., Gilbert E.M., Abraham W.T. et al. Myocardial Gene Expression in Dilated Cardiomyopathy Treated with beta-Blocking Agents Pharmacol 2002, May; 3469180:1357-1365.Lowes B.D., Gilbert E.M., Abraham W.T. et al. Myocardial Gene Expression in Dilated Cardiomyopathy Treated with beta-Blocking Agents Pharmacol 2002, May; 3469180:1357-1365.Lowes B.D., Gilbert E.M., Abraham W.T et al. Myocardial Gene Expression in Dilated Cardiomyopathy Treated with beta-Blocking Agents Pharmacol 2002, May; 3469180:1357-1365.Lowes B.D., Gilbert E.M., Abraham W.T et al. Myocardial Gene Expression in Dilated Cardiomyopathy Treated with beta-Blocking Agents Pharmacol 2002, May; 3469180:1357-1365.Контекст: ...Рядом ученых предпринимались попытки оценить роль полиморфизма 32. Colovo L., Gelatti U., Metra M. et al. Role of (3l-and (32-adrenoreceptor polymorphisms in heart failure: a case -control study//Eur. HeartJ. 2004 Sep,25(17) 1534-154.Контекст: ...Рядом ученых предпринимались попытки оценить роль полиморфизма 32. Colovo L., Gelatti U., Metra M. et al. Role of (3l-and (32-adrenoreceptor polymorphisms in heart failure: a case -control study//Eur. HeartJ. 2004 Sep,25(17) 1534-154.Shioji K., Kokubo Y., Mannami T. et al. Association between hypertension and alpha-adducin, betal-adrenoreceptor, and G-protein Beta3 subunit genes in the Japanese population; the Suita study hypertens//Res. 2004 Jan;27(l):31-7.Shioji K., Kokubo Y., Mannami T. et al. Association between hypertension and alpha-adducin, betal-adrenoreceptor, and G-protein Beta3 subunit genes in the Japanese population; the Suita study hypertens//Res. 2004 Jan;27(l):31-7.Evans W.E., McLeod H.L. Pharmacogenomics -Drug Disposition, Drug Targets, and Side Effects//N. Engl. J. Med. 348:538-49 Feb 6, 2003 №6.Evans W.E., McLeod H.L. Pharmacogenomics -Drug Disposition, Drug Targets, and Side Effects//N. Engl. J. Med. 348:538-49 Feb 6, 2003 №6.Johnson J.A., Zineh I., Puckett B.J. et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metopro lol//Clin-Pharmacol-Ther. 2003 Jul; 44-52.Johnson J.A., Zineh I., Puckett B.J. et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metopro lol//Clin-Pharmacol-Ther. 2003 Jul; 44-52.Stephen В., Liggett BEST Substudy: Betal-adrenergic Receptor Polymorphism and the Prediction of Clinical Response in the beta-Blocker Evaluation of Survival Trial Presented at the 8th Annual Scientific Meeting of the Heart Failure Society of America; September 12-15, 2004; Toronto, Ontario, Canada.Stephen В., Liggett BEST Substudy: Betal-adrenergic Receptor Polymorphism and the Prediction of Clinical Response in the beta-Blocker Evaluation of Survival Trial Presented at the 8th Annual Scientific Meeting of the Heart Failure Society of America; September 12-15, 2004; Toronto, Ontario, Canada.Zhang Y.C., Bui J.D., Shen L., Phillips M.I. Antisense inhibition of beta(l)-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats//Circulation. 2000 Feb 15;101(6):682-8.Zhang Y.C., Bui J.D., Shen L., Phillips M.I. Antisense inhibition of beta(l)-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats//Circulation. 2000 Feb 15;101(6):682-8.

The authors declare that there are no conflicts of interest present.